Fourth Dimension Wealth LLC Raises Stake in Insmed, Inc. $INSM

Fourth Dimension Wealth LLC lifted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 43.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,332 shares of the biopharmaceutical company’s stock after purchasing an additional 710 shares during the quarter. Fourth Dimension Wealth LLC’s holdings in Insmed were worth $235,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of INSM. Adage Capital Partners GP L.L.C. grew its holdings in shares of Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after purchasing an additional 1,799,382 shares during the period. Nuveen LLC acquired a new position in Insmed during the 1st quarter worth approximately $88,351,000. Duquesne Family Office LLC lifted its position in Insmed by 130.7% during the 1st quarter. Duquesne Family Office LLC now owns 1,369,050 shares of the biopharmaceutical company’s stock worth $104,445,000 after acquiring an additional 775,580 shares in the last quarter. 1832 Asset Management L.P. acquired a new position in Insmed during the 1st quarter worth approximately $37,214,000. Finally, Wellington Management Group LLP lifted its position in Insmed by 62.5% during the 1st quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company’s stock worth $93,274,000 after acquiring an additional 470,401 shares in the last quarter.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 6,865 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the transaction, the chief executive officer directly owned 233,924 shares of the company’s stock, valued at $30,035,841.60. This represents a 2.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 24,272 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider directly owned 54,902 shares in the company, valued at approximately $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 152,657 shares of company stock worth $21,442,198 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Insmed Stock Performance

Shares of INSM opened at $182.77 on Wednesday. The business’s 50 day moving average is $154.19 and its two-hundred day moving average is $114.25. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $197.08. The firm has a market cap of $38.98 billion, a price-to-earnings ratio of -32.01 and a beta of 1.05. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same period in the previous year, the company earned ($1.27) earnings per share. The business’s revenue for the quarter was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on INSM shares. Evercore ISI reissued an “outperform” rating and set a $180.00 price target on shares of Insmed in a research report on Wednesday, October 1st. TD Cowen boosted their price target on Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. Guggenheim boosted their price target on Insmed from $125.00 to $172.00 and gave the stock a “buy” rating in a research report on Monday, September 8th. Mizuho set a $196.00 price target on Insmed in a research report on Wednesday, October 29th. Finally, Truist Financial boosted their price target on Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $173.29.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.